Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
What the film says
This trial is for adults with IDH wildtype glioblastoma or gliosarcoma whose tumor has an EGFR amplification or mutation.
The idea: test ERAS-801, an EGFR inhibitor taken by mouth. Some patients take it before and after surgery, others after recurrence, and some older newly diagnosed patients after surgery.
This phase 1 study plans 50 patients and tests safety and side effects. At UCLA's Jonsson Comprehensive Cancer Center in Los Angeles, Phioanh Nghiemphu leads it.
Public record; not medical advice.
Sources behind this film
Adults; IDH wildtype glioblastoma/gliosarcoma with EGFR amplification or mutation; ERAS-801, EGFR inhibitor, by mouth; Before and after surgery; after recurrence; older newly diagnosed after surgery; Phase 1; 50 patients; safety and side effects (+1 more lines)
The drug
PRIMARY OBJECTIVE: I. To evaluate the glucose utilization in the tumor from the glioblastoma patients treated with EGFR inhibitor ERAS-801 (ERAS-801). (Cohort A) II. To evaluate the changes in maximum concentration (Cmax) at dose optimized ERAS-801 correlating with corrected QT interval (QTc) prolongation. (Cohort B) III.
To evaluate the tolerability and efficacy of ERAS-801 recommended phase 2 dose (RP2D) in patients ≥ 70 years of age with newly diagnosed glioblastoma. (Cohort C) IV. To evaluate the 6 month progression free survival (PFS6) and response rate (RR) of ERAS-801 in patients ≥ 70 years of age with newly diagnosed glioblastoma. (Cohort C) SECONDARY OBJECTIVES: I.
ERAS-801, an EGFR inhibitor that can penetrate the central nervous system, binds to the tumor cells that express EGFR and may help shrink or slow the growth of the tumor cells.
The study
This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade IV glioblastoma or gliosarcoma that can be removed by surgery (resectable) and that is growing, spreading, or getting worse (progressive), that has come back after a period of improvement (recurrent) or that is newly diagnosed in an elderly patient.
Glioblastoma is the most common brain cancer in adults and survival rates remain poor despite treatment including surgery, radiation and chemotherapy. EGFR is a protein found on the surface of some cells, to which epidermal growth factor binds, causing the cells to divide. It is found at abnormally high levels on the surface of many types of tumor cells, so these cells may divide excessively in the presence of epidermal growth factor.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.